BiPER Therapeutics

BiPER Therapeutics is a preclinical biotechnology company developing a global pipeline of metabolic small molecules for cancer. Its lead candidate, BPR001, selectively targets BiP/GRP78, a key protein associated with cancer cell survival and linked to poor patient prognosis. BPR001 triggers cancer cell death by inducing endoplasmic reticulum (ER) stress.